Fluocinonide Cream

Fluocinonide

Preferred Pharmaceuticals Inc.
Human Prescription Drug
NDC 68788-8105

Fluocinonide Cream also known as Fluocinonide is a human prescription drug labeled by 'Preferred Pharmaceuticals Inc.'. National Drug Code (NDC) number for Fluocinonide Cream is 68788-8105. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Fluocinonide Cream drug includes Fluocinonide - .5 mg/g . The currest status of Fluocinonide Cream drug is Active.

Drug Information:

Drug NDC:	68788-8105
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name:	Fluocinonide Cream
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type:	Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name:	Fluocinonide
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name:	Preferred Pharmaceuticals Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form:	Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status:	Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:	FLUOCINONIDE - .5 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:	TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Marketing Category:	ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date:	03 Nov, 2021
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date:	20 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number:	ANDA210554
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date:	31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Manufacturer Name:	Preferred Pharmaceuticals Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:	103456
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
NUI:	N0000175576 N0000175450
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:	2W4A77YPAN
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class MOA:	Corticosteroid Hormone Receptor Agonists [MoA]
Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`.
Pharmacologic Class EPC:	Corticosteroid [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class:	Corticosteroid Hormone Receptor Agonists [MoA] Corticosteroid [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDC	Description	Marketing Start Date	Marketing End Date	Sample Available
68788-8105-3	1 TUBE in 1 CARTON (68788-8105-3) / 30 g in 1 TUBE	03 Nov, 2021	N/A	No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Other medicines with the same generic name

Fluocinonide Cream

Fluocinonide

Cream
Preferred Pharmaceuticals Inc.
NDC: 68788-8105

Fluocinonide

Cream
Amneal Pharmaceuticals NY LLC
NDC: 69238-1271

Fluocinonide

Solution
Zydus Pharmaceuticals USA Inc.
NDC: 70710-1284

Fluocinonide

Solution
Zydus Lifesciences Limited
NDC: 70771-1375

Fluocinonide

Cream
Cosette Pharmaceuticals, Inc.
NDC: 0713-0664

Fluocinonide

Ointment
Taro Pharmaceuticals U.S.A., Inc.
NDC: 51672-1264

Fluocinonide

Ointment
Bryant Ranch Prepack
NDC: 63629-2339

Product Elements:

Fluocinonide cream fluocinonide fluocinonide fluocinonide citric acid monohydrate glycerin 1,2,6-hexanetriol polyethylene glycol 3350 polyethylene glycol 8000 propylene glycol stearyl alcohol

Indications and Usage:

Indications and usage fluocinonide cream usp, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

General Precautions:

General systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (hpa) axis suppression, manifestations of cushing's syndrome, hyperglycemia, and glucosuria in some patients. conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of hpa axis suppression by using the urinary free cortisol and acth stimulation tests. if hpa axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. recovery of hpa axis function is generally prompt and complete upon discontinuation of the drug. infrequently, signs and symptoms of steroid withdrawal may occur, requ Read more...

iring supplemental systemic corticosteroids. children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see error! hyperlink reference not valid. ). if irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. as with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues. when used on intertriginous or flexor areas, or on the face, this may occur even with short-term use. in the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. if a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Dosage and Administration:

Dosage and administration fluocinonide cream usp, 0.05% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. if an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications:

Contraindications topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Adverse Reactions:

Adverse reactions the following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. these reactions are listed in an approximate decreasing order of occurrence: burning itching irritation dryness folliculitis hypertrichosis acneiform eruptions hypopigmentation perioral dermatitis allergic contact dermatitis maceration of the skin secondary infection skin atrophy striae miliaria to report suspected adverse reactions, contact amneal pharmaceuticals at 1-877-835-5472 or fda at 1-800-fda-1088 or error! hyperlink reference not valid..

Adverse Reactions Table:

BurningItchingIrritationDrynessFolliculitis

HypertrichosisAcneiform EruptionsHypopigmentationPerioral DermatitisAllergic Contact Dermatitis

Maceration of the SkinSecondary InfectionSkin AtrophyStriaeMiliaria

Use in Pregnancy:

Pregnancy category c corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. the more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. there are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Pediatric Use:

Pediatric use pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary- adrenal (hpa) axis suppression and cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. hpa axis suppression, cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. chronic corticosteroid therapy may interfere with the growth and development of children.

Overdosage:

Overdosage topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see error! hyperlink reference not valid. ).

Description:

Description fluocinonide cream usp, 0.05% is intended for topical administration. the active component in each is the corticosteroid fluocinonide, usp, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy) -6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6a,11b,16a)-. it has the following chemical structure: fluocinonide cream usp, 0.05% contains fluocinonide, usp 0.5 mg/g in a specially formulated cream base consisting of citric acid monohydrate, glycerin, 1,2,6-hexanetriol, polyethylene glycol-3350, polyethylene glycol- 8000, propylene glycol and stearyl alcohol. this white cream is greaseless and free from any foreign particles, non-staining, anhydrous and completely water miscible. the base provides emollient and hydrophilic properties. in the fluocinonide cream usp, 0.05% the active ingredient is totally in solution. formula

Clinical Pharmacology:

Clinical pharmacology topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. the mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. there is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. pharmacokinetics the extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. topical corticosteroids can be absorbed from normal intact skin. inflammation and/or other disease processes in the skin increase percutaneous absorption. occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. thus, occlusive dressings may be Read more...

a valuable therapeutic adjunct for treatment of resistant dermatoses (see error! hyperlink reference not valid. ). once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. corticosteroids are bound to plasma proteins in varying degrees. corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. some of the topical corticosteroids and their metabolites are also excreted into the bile.

Pharmacokinetics:

Pharmacokinetics the extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. topical corticosteroids can be absorbed from normal intact skin. inflammation and/or other disease processes in the skin increase percutaneous absorption. occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see error! hyperlink reference not valid. ). once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. corticosteroids are bound to plasma proteins in varying degrees. corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. some of the topical corticosteroids and their metabolites are also excrete Read more...

d into the bile.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, and impairment of fertility long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

How Supplied:

How supplied fluocinonide cream usp, 0.05% is supplied in 30 g (ndc 68788-8105-3), tubes. store at 20Â° to 25Â°c (68Â° to 77Â°f) [see usp controlled room temperature]. preserve in collapsible tubes or tight containers. distributed by: amneal pharmaceuticals llc bridgewater, nj 08807 rev. 10-2016-00 relabeled by: preferred pharmaceuticals inc.

Package Label Principal Display Panel:

Principal display panel fluocinonide cream usp 0.05%

Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.